



C-RAD appoints Linda Frölén as new CFO

C-RAD AB (publ), is announcing today that Linda Frölén has been appointed new Chief Financial Officer (CFO). She will take office latest September 30, 2024, and is replacing Jonas Reinhammar, Interim CFO since May 13, 2024.

Linda Frölén joins C-RAD from Sedana Medical AB (publ.), where she has served as Head of Group Finance since 2021. Her responsibilities have been to oversee the entire finance function. Previously, Linda has had multiple roles within Group finance, e.g. within life science company Meda AB (publ) and before that many years as auditor at Deloitte in Stockholm.

"We are thrilled to welcome Linda to C-RAD. Her extensive experience and broad expertise in financial management and accounting will be invaluable to us. I look forward to working together with Linda and am confident that she will bring significant value through her personality and professional skills." says Cecilia de Leeuw, CEO C-RAD and President.

"I am honored and happy to be part of the company in this important growth phase. I look forward working together with a strong and engaged team and to contribute to C-RAD's successful development, continuing to establish C-RAD's Surface Guided Radiation Therapy, SGRT, across more clinics and to improve the treatment and quality of life for cancer patients around the world – this feels important to me", says Linda Frölén.

Linda holds a master's degree in business administration from the School of Business, Economics and Law at the University of Gothenburg, with specializations in accounting, corporate finance, and international macroeconomics.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Press Release
20 June 2024 16:15:00 CEST



Attachments

[C-RAD appoints Linda Frölen as new CFO](#)